ข่าวประชาสัมพันธ์ Biogenexis
GenScript Supported Nasal Spray Development for COVID-19 Protection with GMP-grade Antibodies and Subsequently Planned for Long-Term Collaboration with Biogenexis
GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a leading global biotechnology company supported Chulalongkorn University, a research-intensive university in Thailand in developing human anti-SARS-CoV-2 antibodies with antibody production and characterization services. The antibodies were licensed to Hibiocy Co. Ltd., which further developed them into a nasal spray medical device named VAILL COVITRAP(TM). The Thai FDA has approved VAILL COVITRAP(TM) as a Class 4 medical device,